Modulation of S1P in the Treatment of Autoimmune Diseases
We recommend
Co je možné očekávat od ozanimodu v indikaci UC?
Na sympoziu „Zeposia Stand Alone Meeting“ společnosti Bristol Myers Squibb bylo představeno nové léčivo ze skupiny modulátorů receptoru pro sfingosin-1-fosfát (S1P) – ozanimod, a to v indikaci ulcerózní kolitidy (UC). Úvodní vhled do oblasti inovativní léčby UC, v níž je největší posun spojen právě s malými molekulami, nabídl docent Martin Bortlík z Gastroenterologického oddělení Nemocnice České Budějovice. Farmakologické charakteristiky ozanimodu ve svém vystoupení shrnul docent Karel Urbánek z Ústavu farmakologie LF UP a FN Olomouc. Data z…
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on…
Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
As a review article published last year in the journal Drugs suggests, ozanimod is an effective and…
Articles on this topic
Invitation to ZEPOSIA STAND ALONE MEETING
On behalf of Bristol Myers Squibb, we warmly invite you to the Zeposia Stand Alone Meeting, which...
Subscribe
Conferences news
Go to records
Go to records
Most read on this topic
- Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
- Invitation to ZEPOSIA STAND ALONE MEETING
- Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
- Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Journal on this topic
Related topic
Interesting links